Načítá se...
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19), from Wuhan, China, has swept the world. Although the case fatality rate is not high, the number of people infected is large and there is still a large number of patients dying. With the collation and publication of mo...
Uloženo v:
| Vydáno v: | Int J Antimicrob Agents |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7118634/ https://ncbi.nlm.nih.gov/pubmed/32234467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijantimicag.2020.105954 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|